Treatment outcomes of adjunctive surgery in multidrug-resistant and extensively drug-resistant tuberculosis

Opinion

In 2013, the World Health Organization (WHO) reported that 3.5% and 20.5% of new and previously treated tuberculosis (TB) cases were multidrug-resistant tuberculosis (MDR-TB, resistant to both isoniazid and rifampicin), respectively, and 9.0% of them developed extensively drug-resistant tuberculosis (XDR-TB, resistant to isoniazid, rifampicin, a fluoroquinolone, and 1 or greater injectable agent). The WHO has estimated a global prevalence of 660,000 cases of MDR-TB and 150,000 MDR-TB related deaths annually. A previous multi-country study revealed that among 1,278 MDR-TB cases, around 7% had XDR-TB. Only 136,000 MDR-TB cases (45.3%) among estimated 300,000 MDR-TB cases have been diagnosed and 97,000 cases (32.3%) are treated using appropriate regimens based on drug susceptibility testing (DST). In 2013, the treatment success rate of MDR-TB is only 48.0%; around 47,000 cases improved clinically and biologically. Diagnosis and treatment of these cases are largely suboptimal global programmatic capacity. Currently, MDR-TB/XDR-TB treatment regimens are lengthy, costly, toxic, and associated with unfavorable treatment outcomes as compared with drug-susceptible TB. The previous largest observational, retrospective, meta-analytic cohort study of about 10,000 MDR-TB cases (at least 400 cases of them being XDR-TB) demonstrated 62% of treatment success rate, 7% of failing or relapsing rate, 17% of defaulting rate, and 9% of death rate. Among XDR-TB subgroup, only 40% reached the treatment success, 22% failed treatment or relapsed, 16% defaulted, and 15% died. Among the subgroup of XDR-TB with severe drug-resistance pattern, only 19% achieved treatment success. Thoracic surgery for MDR-TB/XDR-TB is a potentially beneficial adjunctive treatment. The first surgical intervention on a patient with TB was performed by Barry E in 1726, followed by Forlannini C in 1882, who carried out an artificial pneumothorax. A favorable outcomes for 72 MDR-TB/XDR-TB patients undergoing surgical lung resection in the country of Georgia was reported that 49(68%) were cured, 6(8%) were completed. Nevertheless, 4(5.5%) of them were treatment failure, 5(7%) were defaulters, and 4(5.5%) were dead. The surgical procedures were performed as the following: 11% of pneumonectomy, 54% of lobectomy, and 35% of segmentectomy. With utilizing a combination of personal medical treatment for MDR-TB/XDR-TB according to the WHO guidelines and adjunctive surgical treatment, a high rate of favorable treatment outcomes (82%) was obtained. Favorable treatment outcomes was included in 90% of those with MDR-TB and 67% of those with XDR-TB. Surgical treatment for drug-resistant TB has been demonstrated to be safe and effective, with operative mortality rates similar to surgery for lung cancer. Two specific indications for lung resection in drug-resistant TB are failed medical treatment with persistent sputum positivity and patients with medical treatment and negative sputum smear who have bronchiectasis or localized cavitary disease. A systematic review and meta-analysis of adjunctive pulmonary resection for MDR-TB patients that included 15 studies (a total sample size of 949) demonstrated the overall cure rate of 84%. A previous study of 5 Japanese XDR-TB cases revealed that two cases with pneumonectomy and three cases with upper lobectomy (preoperative chemotheraphy with sparfloxacin+pyrazinamide+cycloserine+ethionamide+enomycin; gatifloxacin+cycloloserine+enviomyacin; p-para-aminosalicylic acid; gatifloxacin+pyrazinamide+cycloserine; gatifloxacin+pyrazinamide+enomycin; and kanamycin+cycloserine+ethionamide+para-aminosalicylic acid+sultamicillin tosilate) After the surgical operation, most patients attained sputum negative status, and return to their normal daily activities. The duration of postoperative antituberculous chemotherapy ranged from 12-25months with the median of 19months and all of them remained free from disease at the time of follow-up. In conclusion, There has been lack of randomized controlled trials of surgical resections although observational studies with surgical interventions have demonstrated a high treatment success rate when used as adjunctive treatment in MDR-TB/XDR-TB patients. Adjunctive surgical interventions may lay a significant role in improving clinical outcomes in many cases of complicated MDR-TB/XDR-TB with localized and tissue destruction accompanying failure to become culture negative.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

Citation: Cheepsattayakorn A, Cheepsattayakorn R. Treatment outcomes of adjunctive surgery in multidrug-resistant and extensively drug-resistant tuberculosis. MOJ Surg. 2017;5(2):194. DOI: 10.15406/moj.2017.05.00109

© 2017 Cheepsattayakorn et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.